Moderna (MRNA) Assets (2017 - 2026)

Moderna (MRNA) has reported Assets for 10 consecutive years, with $11.0 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets fell 8.73% year-over-year to $11.0 billion in Q2 2026; TTM through Jun 2026 was $11.0 billion, a 8.73% decrease from a year earlier, with the FY2025 full-year figure at $12.3 billion, down 12.76% from the prior year.
• Assets was $11.0 billion for Q2 2026 at Moderna, down from $11.5 billion in the prior quarter.
• Over five years, Assets peaked at $27.6 billion in Q1 2022 and troughed at $11.0 billion in Q2 2026.
• A 5-year average of $18.0 billion and a median of $16.3 billion in 2024 frame the typical range for Assets.
• Across the five-year window, Assets jumped 117.5% in 2022 and tumbled 30.66% in 2024, its largest moves.
• Over 5 years, Assets stood at $25.9 billion in 2022, then retreated by 28.74% to $18.4 billion in 2023, then declined by 23.25% to $14.1 billion in 2024, then retreated by 12.76% to $12.3 billion in 2025, then dropped by 11.16% to $11.0 billion in 2026.
• The last three Assets figures came in at $11.0 billion (Q2 2026), $11.5 billion (Q1 2026), and $12.3 billion (Q4 2025), per Business Quant data.